GlycoTech was founded in 1991 and remains today as one of the premier companies focusing on the biological functions and medical applications of glycoconjugates.   The company has established its own research programs and has developed a large intellectual property portfolio.  Through its catalog business, GlycoTech has also established one of the largest libraries of rare carbohydrate reagents and technologies worldwide.

GlycoTech has maintained a corporate alliance with Novartis for the past six years to develop small molecule mimics of carbohydrate ligands as potent antagonists for the aberrant extravasation of lymphocytes from the bloodstream during transplantation-induced reperfusion injury. 

In addition, licensing agreements were recently established with Chiron Corporation for worldwide sales in cancer diagnostics using anti-carbohydrate tumor markers owned by GlycoTech.

Research agreements have also been established with the National Institutes of Health, the University of Pennsylvania, the University of Rochester, and the Chicago Institute for Neurosurgery and Neuroresearch.

GlycoTech is actively seeking other pharmaceutical partners and offers a combined range of expertise focusing on the Glycobiology area. The corporate structure and strategy of GlycoTech allows its partners to quickly obtain this unique expertise and avoid the obligations encountered with the fixed financial responsibilities associated with internal organic growth.  We welcome the opportunity to meet with all interested parties to explore mutually constructive collaborations.

FINE CHEMICALS and REAGENTS BUSINESS

The purpose of this division of GlycoTech is to make techniques and reagents available to all scientists in order to broaden investigations of carbohydrates into other fields of research such as Cell Biology, Immunology, Neurobiology, and Molecular Biology. The first section of the catalog contains some useful protocols written by well known scientists covering a wide range of topics in Glycobiology. The following sections contain a variety of unique carbohydrate reagents that allow many of these protocols to be followed in laboratories not necessarily specializing in Glycobiology. This catalog also welcomes the participation of scientists within this field with the objective to actively support their research and discoveries. GlycoTech's long-term goal is to use our technology and reagents for research towards new discoveries of the biological functions of carbohydrates based on the interaction of glycoconjugates and their receptors. We hope that this catalog fulfills these goals and promotes the application of discoveries to the biomedical community.